| Source: Orion Oyj
ORION CORPORATION
MANAGERS’ TRANSACTIONS
2 MAY 2025 at 11.45 EEST
Orion Corporation: Managers’ transactions – Henrik Stenqvist
Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.
Orion Oyj – Managers’ Transactions
____________________________________________
Person subject to the notification requirement
Name: Henrik Stenqvist
Position: Member of the Board/Deputy member
Issuer: Orion Oyj
LEI: 74370029VAHCXDR7B745
Notification type: INITIAL NOTIFICATION
Reference number: 106243/4/4
____________________________________________
Transaction date: 2025-04-30
Venue: OFF-EXCHANGE LIIKETOIMET (XOFF)
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE
Transaction details
(1): Volume: 415 Unit price: 0 EUR
Aggregated transactions (1):
Volume: 415 Volume weighted average price: 0 EUR
Orion Corporation
| Liisa Hurme President and CEO | Olli Huotari Executive Vice President, |
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orionpharma.com
Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion’s net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion’s A and B shares are listed on Nasdaq Helsinki.
